JOINT PRESS RELEASE - Industry Welcomes the European Commission Commitment to a Sustainable and Competitive Off-Patent Biologics Market
Brussels, 6 October 2015.- The European pharmaceutical industry welcomes the initiative by the European Commission Directorate General for the Internal Market, Industry, Entrepreneurship and SMEs (DG Grow) to host on 6 October 2015, an event on access to biosimilar medicines in Europe.
JOINT PRESS RELEASE - Global Pharmaceutical Associations Welcome MEDICRIME Convention, Landmark Tool to Curb Global Medicines Counterfeiting
Brussels, 1 October 2015 – A unique international tool criminalizing the trade of counterfeit medicines, the Medicrime Convention, will enter into force on 1st January 2016, after 5 countries out of its 24 signatories completed the ratification process. The Medicrime Convention, launched by the Council of Europe in December 2010 is opened for signature by all countries in the world and aims to curb what it defines as counterfeit (falsified) medicines, that is medicines whose identity and/or source have been falsely represented.
The Riga Roadmap sets out an Action Plan for EU and National Policy Makers to Deliver Sustainable, Equitable and Participatory European Health Systems
Brussels, 31 August 2015 – European health stakeholders are pleased to announce the publication of the Riga Roadmap, an action plan to make EU health systems sustainable, equitable and participatory. The Roadmap is a result of the Universal Healthcare Conference, held in Riga, 28th-29th June, where the signatories of the Roadmap – the European Generic and Biosimilar medicines Association, EGA; the European Federation of Pharmaceutical Industries and Associations, EFPIA; the European Patients’ Forum, EPF; and the European Public Health Alliance, EPHA – joined forces to set out this plan for the future.
Statement on GVK BIO EU referral
27 July 2015 - The European Generic and Biosimilar medicines Association (EGA) and its members have an absolute commitment to quality for medicines in Europe and to the well-being and safety of patients. Further to the European Commission’s (EC) decision on the GVK CRO investigation which is entirely in line with the previously published European Medicines Agency’s (EMA) recommendation, EGA members have been active in conjunction with the competent authorities since the EMA has issued their advice and will continue to do so. The EMA indicates that there is no evidence of harm or lack of effectiveness linked to the conduct of studies by GVK Biosciences and that medicines considered critically important for patients will remain available.
Successful Link with Germany’s securPharm Makes EMVS a Reality
Brussels, 23 July 2015 - The European Medicines Verification System (EMVS) has passed another significant milestone in its development process by successfully implementing its first Hub connection with a Member State. This achievement is a major step along the road to securing the legitimate pharmaceutical supply chain against the risk of falsified medicines.
27 January 2016
28 - 29 January 2016
08 - 09 March 2016
How to Increase Patient Access to Generic Medicines in European Healthcare Systems
EGA Vision 2015, the Way forward for more Efficient Regulatory Environment for Generic and Biosimilar Medicines
GfK Final Report - Factors Supporting a Sustainable European Biosimilar Medicines Market GfK Final Report- Factors Supporting a Sustainable European Biosimilar Medicines Market
EGA Biosimilars Handbook
English version EGA_BIOSIMILARS_handbook_en.pdf